PURPOSE: To assess rates and causes of mortality in patients with Wilms tumor (WT). METHODS: Through 2002, 6,185 patients enrolled onto the National Wilms Tumor Study between 1969 and 1995 were actively observed. Deaths were classified on the basis of medical records as the result of original disease, late effects (including second malignant neoplasms [SMNs], cardiac causes, pulmonary disease, and renal failure), or other causes. Standardized mortality ratios (SMRs) and Cox regression were used to assess the effects of sex, age, and calendar period of diagnosis on mortality. RESULTS: Within 5 years of WT diagnosis, 819 deaths occurred, and 159 deaths occurred among 4,972 known 5-year survivors. The SMR was 24.3 (95% CI, 22.6 to 26.0) for the first 5 years, was 12.6 (95% CI, 10.0 to 15.7) for the next 5 years, and remained greater than 3.0 thereafter. For deaths in the first 5 years, the mortality risk decreased by 5-year calendar period of diagnosis (rate ratio [RR] = 0.78 per period). No such trend occurred for later deaths. Among 5-year survivors, 62 deaths were attributed to late effects of treatment or disease, including 27 to SMNs. A trend of decreased risk with calendar period of diagnosis was observed for late-effects mortality (RR = 0.86; 95% CI, 0.67 to 1.10) and for SMN mortality (RR = 0.82; 95% CI, 0.55 to 1.21). CONCLUSION: Although the survival outlook for WT patients has improved greatly over time, survivors remain at elevated risk for death many years after their original diagnosis.
PURPOSE: To assess rates and causes of mortality in patients with Wilms tumor (WT). METHODS: Through 2002, 6,185 patients enrolled onto the National Wilms Tumor Study between 1969 and 1995 were actively observed. Deaths were classified on the basis of medical records as the result of original disease, late effects (including second malignant neoplasms [SMNs], cardiac causes, pulmonary disease, and renal failure), or other causes. Standardized mortality ratios (SMRs) and Cox regression were used to assess the effects of sex, age, and calendar period of diagnosis on mortality. RESULTS: Within 5 years of WT diagnosis, 819 deaths occurred, and 159 deaths occurred among 4,972 known 5-year survivors. The SMR was 24.3 (95% CI, 22.6 to 26.0) for the first 5 years, was 12.6 (95% CI, 10.0 to 15.7) for the next 5 years, and remained greater than 3.0 thereafter. For deaths in the first 5 years, the mortality risk decreased by 5-year calendar period of diagnosis (rate ratio [RR] = 0.78 per period). No such trend occurred for later deaths. Among 5-year survivors, 62 deaths were attributed to late effects of treatment or disease, including 27 to SMNs. A trend of decreased risk with calendar period of diagnosis was observed for late-effects mortality (RR = 0.86; 95% CI, 0.67 to 1.10) and for SMN mortality (RR = 0.82; 95% CI, 0.55 to 1.21). CONCLUSION: Although the survival outlook for WT patients has improved greatly over time, survivors remain at elevated risk for death many years after their original diagnosis.
Authors: G J D'Angio; N Breslow; J B Beckwith; A Evans; H Baum; A deLorimier; D Fernbach; E Hrabovsky; B Jones; P Kelalis Journal: Cancer Date: 1989-07-15 Impact factor: 6.860
Authors: M C Cardous-Ubbink; R C Heinen; N E Langeveld; P J M Bakker; P A Voûte; H N Caron; F E van Leeuwen Journal: Pediatr Blood Cancer Date: 2004-06 Impact factor: 3.167
Authors: A C Mertens; Y Yasui; J P Neglia; J D Potter; M E Nesbit; K Ruccione; W A Smithson; L L Robison Journal: J Clin Oncol Date: 2001-07-01 Impact factor: 50.717
Authors: Rand N Wilcox Vanden Berg; Emily N Bierman; Megan Van Noord; Henry E Rice; Jonathan C Routh Journal: Urol Oncol Date: 2015-08-05 Impact factor: 3.498
Authors: Rodrigo B Interiano; Noel Delos Santos; Sujuan Huang; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; Daniel M Green; Andrew M Davidoff Journal: Cancer Date: 2015-04-01 Impact factor: 6.860
Authors: Jean S Lee; Benjamin Padilla; Steven G DuBois; Aris Oates; John Boscardin; Robert E Goldsby Journal: Pediatr Blood Cancer Date: 2015-03-25 Impact factor: 3.167
Authors: M Hassan Alkazemi; Zachary R Dionise; Ruiyang Jiang; Steven Wolf; Gina-Maria Pomann; Elisabeth T Tracy; Henry E Rice; Jonathan C Routh Journal: J Pediatr Surg Date: 2019-05-31 Impact factor: 2.545
Authors: Conrad V Fernandez; Elizabeth J Perlman; Elizabeth A Mullen; Yueh-Yun Chi; Thomas E Hamilton; Kenneth W Gow; Fernando A Ferrer; Douglas C Barnhart; Peter F Ehrlich; Geetika Khanna; John A Kalapurakal; Tina Bocking; Vicky Huff; Jing Tian; James I Geller; Paul E Grundy; James R Anderson; Jeffrey S Dome; Robert C Shamberger Journal: Ann Surg Date: 2017-04 Impact factor: 12.969
Authors: Conrad V Fernandez; Elizabeth A Mullen; Yueh-Yun Chi; Peter F Ehrlich; Elizabeth J Perlman; John A Kalapurakal; Geetika Khanna; Arnold C Paulino; Thomas E Hamilton; Kenneth W Gow; Zelig Tochner; Fredric A Hoffer; Janice S Withycombe; Robert C Shamberger; Yeonil Kim; James I Geller; James R Anderson; Paul E Grundy; Jeffrey S Dome Journal: J Clin Oncol Date: 2017-12-06 Impact factor: 44.544
Authors: Peter F Ehrlich; James R Anderson; Michael L Ritchey; Jeffrey S Dome; Daniel M Green; Paul E Grundy; Elizabeth J Perlman; John A Kalapurakal; Norman E Breslow; Robert C Shamberger Journal: J Clin Oncol Date: 2013-02-04 Impact factor: 44.544